Marion Merrell Dow
More than doubles its research funding to rational drug design company Affymax, the companies announce July 23. MMD's funding of Affymax totaled $7.5 mil. during 1991 ("The Pink Sheet" June 17, 1991, In Brief). The new expansion also extends the companies' initial three-year collaboration until 1997. The collaboration is targeting arthritis, cancer and autoimmune diseases.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth